We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · January 07, 2021

Patisiran for Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

The Lancet Neurology


Additional Info

The Lancet Neurology
Long-Term Safety and Efficacy of Patisiran for Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy: 12-Month Results of an Open-Label Extension Study
Lancet Neurol 2021 Jan 01;20(1)49-59, D Adams, M Polydefkis, A González-Duarte, J Wixner, AV Kristen, HH Schmidt, JL Berk, IA Losada López, A Dispenzieri, D Quan, IM Conceição, MS Slama, JD Gillmore, T Kyriakides, S Ajroud-Driss, M Waddington-Cruz, MM Mezei, V Planté-Bordeneuve, S Attarian, E Mauricio, TH Brannagan, M Ueda, E Aldinc, JJ Wang, MT White, J Vest, E Berber, MT Sweetser, T Coelho

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading